Myosin Therapeutics Awarded $2M Florida Grant for GBM Clinical Trial

The funding will support the company's STAR-GBM Phase 1/2 trial evaluating MT-125 in newly diagnosed glioblastoma patients.

Mar. 25, 2026 at 4:39am

Got story updates? Submit your updates here. ›

Myosin Therapeutics, a biotechnology company based in Jupiter, Florida, has been awarded $2 million in funding from the Florida Department of Health's Casey DeSantis Florida Cancer Innovation Fund (FCIF) to support the company's STAR-GBM Phase 1/2 clinical trial evaluating its lead oncology therapeutic candidate MT-125 in patients newly diagnosed with glioblastoma (GBM).

Why it matters

The FCIF grant reflects the growing strength of Florida's life sciences community in advancing innovative cancer therapies. The funding will help accelerate the clinical development of MT-125, which has received Orphan Drug Designation for malignant gliomas and Fast Track Designation for glioblastoma, supporting an accelerated regulatory pathway for therapies addressing serious diseases with significant unmet medical need.

The details

The Phase 1/2 STAR-GBM clinical trial represents the first clinical evaluation of MT-125 and is being conducted in collaboration with Mayo Clinic, with all three Mayo Clinic clinical research units in the U.S. participating in the study. The Phase 1 portion will evaluate safety, tolerability, and pharmacokinetics, while generating early clinical data to inform the Phase 2 dose expansion portion.

  • The STAR-GBM clinical trial is currently underway.
  • The funding from the Florida Department of Health was awarded in March 2026.

The players

Myosin Therapeutics

A biotechnology company based in Jupiter, Florida, developing first-in-class therapies for oncology and CNS disorders by targeting molecular nanomotor proteins. The company's lead program is MT-125, which is being developed for the treatment of multiple aggressive cancers.

Casey DeSantis Florida Cancer Innovation Fund (FCIF)

A statewide initiative designed to accelerate the development of innovative cancer therapies and strengthen the life sciences ecosystem in Florida by supporting promising research programs and emerging biotechnology companies.

Mayo Clinic

A leading academic medical center in Florida that is playing an important role in advancing new therapies through early-stage clinical trials. Mayo Clinic's Florida campus is participating in the STAR-GBM trial, bringing specialized neuro-oncology expertise and clinical trial infrastructure to evaluate MT-125 in patients with newly diagnosed GBM.

Got photos? Submit your photos here. ›

What they’re saying

“We are honored to receive support from the Casey DeSantis Florida Cancer Innovation Fund as we bring MT-125 to patients. This funding helps support the continued progress of our Phase 1/2 STAR-GBM trial and reflects the growing strength of Florida's life sciences community in advancing innovative cancer therapies.”

— Dr. Courtney Miller, Co-Founder and CEO of Myosin Therapeutics

“This support from the Florida Department of Health will help accelerate the clinical development of MT-125 and strengthen Florida's role as a growing hub for biotechnology innovation. Programs like FCIF play an important role in enabling emerging biotechs to translate promising scientific discoveries into clinical programs that can ultimately benefit patients.”

— Dr. Patrick Griffin, Co-founder and Chief Scientific Officer of Myosin Therapeutics

What’s next

The Phase 1 portion of the STAR-GBM trial will evaluate the safety, tolerability, and pharmacokinetics of MT-125, while generating early clinical data to inform the Phase 2 dose expansion portion of the study.

The takeaway

The Florida Department of Health's $2 million grant to Myosin Therapeutics for the STAR-GBM clinical trial highlights the state's growing role in supporting innovative cancer research and the development of promising new therapies to address serious diseases like glioblastoma, which has significant unmet medical need.